FindTrial
Sign In

Thalidomide with Etanercept combination therapy for tumor cachexia: an open label randomized controlled trial

A feasibility study about Thalidomide with Etanercept combination therapy in tumor cachexia

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-TRC-12002335
Enrollment
Unknown
Registered
2012-06-08
Start date
2012-07-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

tumor cachexia

Interventions

3:Etanercept
1:Thalidomide
2:Thalidomide combined with Etanercept

Sponsors

Shuyang People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: Outpatient and hospitalized 18-80 years old patients with advanced (clinical stage III-IV) tumor cachexia, unlimited to gender, tumor site and classification, clinical assessment of life expectancy of more than four months, is being or stop accepting radical, palliative or supportive care of cancer patients.

Exclusion criteria

Exclusion criteria: During the medication treatment, serious complications such as deep vein thrombosis, can not continue without significant improvement after four weeks treatment of symptomatic patients who unwilling to accept to continue treatment and the patients want to automatically withdraw.

Design outcomes

Primary

MeasureTime frame
BMI and LBM;dual-energy X-ray CT;biological marker;—

Countries

China

Contacts

Public ContactYe-Ting Zhou, Jian Xu
zyt5009@163.com+86 18796492533

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026